Sterile Processing

Q: My hospital is implementing a third-party reprocessing program. I am not in support of this. I cannot believe that a company can take a single-use device and make it safe again.  I am all for containing costs but not at the risk of a patient safety. What do you know about this process?

Infection prevention continues to be an issue that is top of mind for GI professionals. When thinking of gastroenterology infection prevention, it traditionally has been in terms of reprocessing endoscopes and post-procedure patient phone call to assess for infections. Infection prevention for GI encompasses so much more than those two tasks - it includes correct use of personal protective equipment (PPE), personal hygiene, engineering controls of the physical environment, cleaning and disinfection of surfaces, training, continuing education, written operating procedures, and of course documentation. Earlier this year, SGNA released practice documents focused on infection prevention. The new document, Standard of Infection Prevention in the Gastroenterology Setting, brings to light an important point that is often overlooked when we discuss infection prevention: Prevention for the whole team.

A simple paper sheet made by scientists at Uppsala University can improve the quality of life for millions of people by removing resistant viruses from water. The sheet, made of cellulose nanofibers, is called the mille-feuille filter as it has a unique layered internal architecture resembling that of the French puff pastry mille-feuille ("thousand leaves").

A potential drug therapy developed at the University of Pittsburgh Center for Vaccine Research (CVR) has proven effective against tough bacterial biofilms and a deadly respiratory virus simultaneously. The drug outperforms traditional therapies in the laboratory setting.

When assigning blame for a number of outbreaks linked to contaminated and improperly processed duodenoscopes, a U.S. Senate report released in January pointed equally to hospitals, scope and equipment  manufacturers and the Food and Drug Administration (FDA) for failing to act on known risks of infection.  Duodenoscopes have been implicated in at least 250 patient infections with carbapenem-resistant enterobacteriaceae (CRE) between 2012 and the spring of 2015.